Lambert-Eaton Myasthenic Syndrome

• VGCC antibody-mediated calcium channel blockade: Approximately 85% of LEMS patients develop IgG antibodies against P/Q-type voltage-gated calcium channels (Cav2.1), which are the predominant calcium channel subtype at the neuromuscular junction presynaptic terminal. A smaller proportion (10–15%) develop antibodies against N-type channels (Cav2.2). These antibodies bind to the extracellular domains of the calcium channel α1 subunit and trigger complement-mediated destruction and cross-linking-induced internalization of the channels. The resulting reduction in functional calcium channels on the presynaptic membrane is the central mechanism: normally, an action potential depolarizes the presynaptic terminal, opening VGCCs and allowing calcium influx that triggers acetylcholine release. With reduced calcium channel density and function, calcium influx is impaired, directly decreasing the number of acetylcholine quanta released per action potential. This contrasts sharply with myasthenia gravis, where antibodies target postsynaptic acetylcholine receptors.

• Impaired calcium-dependent acetylcholine exocytosis: The reduced calcium influx fails to adequately activate the calcium-sensing machinery required for SNARE complex-mediated fusion of acetylcholine vesicles with the presynaptic membrane. Normally, micromolar concentrations of intracellular calcium activate synaptotagmin, triggering coordinated SNARE protein interactions (SNAP-25, syntaxin, VAMP) that facilitate vesicle fusion and acetylcholine release. The quantitative reduction in acetylcholine quanta per action potential—from the normal 100–150 quanta down to 10–20 in LEMS—results in summation of excitatory postsynaptic potentials (EPSPs) that fail to reach threshold in non-repeated stimuli, explaining why initial voluntary contractions are weak but repeated stimulation improves strength through summation.

• Postsynaptic compensation and the distinctive "warm-up" phenomenon: When a muscle is stimulated repetitively (high-frequency), presynaptic terminals accumulate calcium despite the reduced number of functional VGCCs, progressively improving acetylcholine release and muscle strength over seconds to minutes—the characteristic "warm-up" effect. Additionally, there is often denervation-like upregulation of postsynaptic acetylcholine receptors, which partially compensates for the reduced acetylcholine quanta by increasing sensitivity. However, this compensation is insufficient to restore normal neuromuscular transmission at rest or with low-frequency activity, explaining the clinical pattern of progressive weakness with activity that improves with brief high-intensity exercise.

• Autonomic dysfunction mechanisms: VGCC antibodies are not limited to the neuromuscular junction; they also target presynaptic terminals in autonomic ganglia and the enteric nervous system. Autonomic P/Q and N-type calcium channels mediate sympathetic and parasympathetic neurotransmitter release (norepinephrine, acetylcholine). Calcium channel dysfunction at these sites impairs autonomic ganglionic transmission, resulting in dry mouth, decreased sweating, constipation, erectile dysfunction, and orthostatic hypotension. These autonomic features are present in approximately 70% of LEMS patients and can be prominent enough to cause significant morbidity.

• Immune system dysregulation and malignancy link: LEMS associated with SCLC is thought to arise because SCLC cells aberrantly express VGCC antigens (particularly P/Q-type), which bypass immune tolerance mechanisms. The tumor triggers an immune response against these channels, with both cell-mediated and humoral (antibody-mediated) immunity directed at VGCCs on both tumor cells and the presynaptic neuromuscular junction. In contrast, "seronegative" LEMS (15% of patients lacking VGCC antibodies) may involve N-type calcium channel antibodies or other undiscovered immune mechanisms.

• Small-cell lung cancer (SCLC) and paraneoplastic LEMS: Approximately 50–60% of LEMS patients harbor an underlying malignancy at diagnosis or develop one within the first 5 years of symptom onset. SCLC is the most common associated malignancy, present in 70–80% of cancer-associated LEMS cases. SCLC cells express VGCC antigens that cross-react with neuronal VGCCs, triggering anti-VGCC antibody production. The paraneoplastic mechanism suggests that immunologic attack on the tumor inadvertently damages the neuromuscular junction. Annual screening with chest CT imaging is recommended in all patients, with particular vigilance in heavy smokers and those with respiratory symptoms. Malignancy may be detected months to years after LEMS symptom onset, emphasizing the need for continued surveillance in seronegative patients.

• Non-malignant/idiopathic LEMS: Approximately 40–50% of LEMS patients have no identifiable malignancy and are classified as having idiopathic or autoimmune LEMS. These patients develop anti-VGCC antibodies through autoimmune mechanisms unrelated to cancer, often in the context of other autoimmune diseases (thyroiditis, systemic lupus erythematosus, celiac disease). Genetic factors, including HLA-B8 and HLA-DR3 associations, appear to predispose to idiopathic LEMS. Idiopathic LEMS typically has a better long-term prognosis than cancer-associated disease and may respond more dramatically to immunosuppressive therapy.

• HLA associations and genetic predisposition: HLA-B8 and HLA-DR3 alleles are significantly overrepresented in LEMS patients, particularly those with the idiopathic form, suggesting that these MHC molecules present VGCC epitopes that break immune tolerance. These genetic factors likely contribute to aberrant T-cell help for anti-VGCC B-cell and plasma cell responses.

• Age of onset and demographic factors: Idiopathic LEMS typically presents in younger adults (30–50 years), while cancer-associated LEMS typically occurs in older adults (50–70 years) with heavy smoking histories. No clear gender predominance exists.

• Insidious progressive proximal muscle weakness: The hallmark presenting symptom is progressive weakness predominantly affecting the lower extremities and trunk, with relative sparing of ocular and bulbar muscles (distinguishing LEMS from myasthenia gravis). Weakness typically develops over weeks to months and is characteristically greater distally in the lower extremities than proximally (contrasting with the proximal > distal pattern of many myopathies). Patients report difficulty rising from chairs, climbing stairs, and walking. The weakness fluctuates throughout the day and with activity level but follows a distinctive pattern: muscles are weakest at rest or after periods of inactivity and improve with brief high-intensity exercise, the "warm-up phenomenon" that is virtually pathognomonic for LEMS. Patients often describe that their strength improves paradoxically with exercise—a key historical clue that should prompt suspicion for LEMS.

• Fatigue and activity-related symptoms: Patients frequently report disabling fatigue distinct from the weakness itself, often describing a sensation of muscles "running out of battery." Unlike myasthenia gravis, where fatigue is typically insidious throughout the day, LEMS fatigue can actually improve during or shortly after intense activity due to the warm-up phenomenon.

• Autonomic symptoms: Approximately 70% of LEMS patients exhibit autonomic dysfunction including dry mouth (very common, present in >50% of patients), decreased sweating, constipation (sometimes severe), erectile dysfunction in men, and orthostatic hypotension. These autonomic features often precede or accompany neuromuscular symptoms and may be underrecognized. Autonomic dysfunction reflects VGCC antibody-mediated damage at autonomic ganglia and parasympathetic/sympathetic nerve terminals throughout the body. Some patients may present primarily with autonomic complaints before neuromuscular weakness is apparent.

• Areflexia as a distinctive physical exam finding: On examination, absent or severely diminished deep tendon reflexes (DTRs) are present in >90% of LEMS patients. This finding is distinctive because the patient typically has generalized weakness that would normally be expected to increase reflexes via spasticity, yet reflexes are profoundly reduced. The areflexia likely reflects both neuromuscular junction dysfunction affecting muscle contraction amplitude and secondary changes in spinal reflex circuits. Post-tetanic potentiation (PTP) of reflexes is a characteristic finding: if a reflex is initially absent or hypoactive, vigorous contraction of the tested muscle (e.g., having the patient squeeze their fists vigorously) for 10 seconds can cause the subsequently elicited reflex to become brisk—this is a distinctive feature of LEMS and reflects calcium accumulation in presynaptic terminals during intense activity.

• Preserved ocular and bulbar function: Unlike myasthenia gravis, which typically causes ptosis, diplopia, and facial weakness, LEMS characteristically spares extraocular muscles and bulbar muscles. Ocular findings are present in <5% of LEMS patients. The preservation of ocular function is a key clinical differentiator and is related to different calcium channel subtype distribution in ocular motor nerves.

• Muscle pain and cramping: Some LEMS patients report myalgias or muscle cramps, particularly in the legs, though these are not as prominent as in some other neuromuscular disorders.

• Symptom worsening in heat: Paradoxically, some patients report that symptoms worsen with heat exposure (hot showers, warm weather), which may relate to altered calcium channel kinetics or metabolic factors in the presynaptic terminal.

• Rare severe presentations: In fulminant cases, particularly cancer-associated LEMS, respiratory muscle weakness and bulbar dysfunction can occur, necessitating close monitoring and potential ICU support. However, life-threatening presentations at onset are uncommon.

• Serum antibody testing for voltage-gated calcium channels: Anti-P/Q-type and anti-N-type VGCC antibodies detected by radioimmunoassay or ELISA are highly specific for LEMS when positive. Approximately 85% of patients have detectable anti-P/Q-type VGCC IgG antibodies, and an additional 5–10% have anti-N-type antibodies. A positive VGCC antibody test is virtually diagnostic of LEMS and has >95% specificity. However, 15% of LEMS patients are seropositive for VGCC antibodies and are classified as "seronegative LEMS," requiring reliance on clinical and electrophysiological findings. Antibody titers do not reliably correlate with disease severity. Testing should be performed at a specialized neuromuscular laboratory; antibody negativity does not exclude LEMS if clinical and electrophysiological features are compelling.

• Repetitive nerve stimulation (RNS) with the distinctive "incremental response": RNS is the gold standard diagnostic test for LEMS and demonstrates the pathognomonic incremental response (also called "posttetanic potentiation" on RNS). In normal subjects, RNS at 3 Hz produces a decrement <10% in the compound muscle action potential (CMAP) amplitude. In LEMS, initial RNS shows a pathological decremental response (>10% decline in CMAP amplitude)—similar to myasthenia gravis—but this decrement is followed by a distinctive "incremental response" after brief (10 seconds) high-frequency stimulation (20–50 Hz). Specifically, the CMAP amplitude increases dramatically (typically >100% and often >200%) above baseline within the first 2–3 minutes following high-frequency stimulation, a finding seen in only a small percentage of other conditions. This incremental response reflects the mechanism of LEMS: calcium accumulation in presynaptic terminals during high-frequency stimulation transiently improves acetylcholine release, manifesting as CMAP amplitude potentiation. RNS sensitivity for LEMS is 60–80%, making it less sensitive than in myasthenia gravis but highly specific when positive. The incremental response is present in both VGCC antibody–positive and seronegative LEMS and is the most sensitive neurophysiological finding for the diagnosis.

• Single-fiber electromyography (SFEMG): SFEMG demonstrates increased jitter (variability in the time interval between action potentials of muscle fiber pairs) and frequent blocking (intermittent failure of neuromuscular transmission), consistent with neuromuscular junction dysfunction. SFEMG has >95% sensitivity for LEMS but lacks specificity, as similar findings occur in myasthenia gravis and other neuromuscular junction disorders. SFEMG is useful to confirm neuromuscular junction involvement when RNS is equivocal or negative, particularly in seronegative LEMS. SFEMG is labor-intensive and not required for diagnosis when RNS demonstrates the characteristic incremental response.

• Brief high-frequency stimulation test (clinical bedside assessment): While not a formal diagnostic test, clinicians can assess for post-tetanic potentiation of strength by having patients maximally contract a muscle group for 10 seconds, then immediately re-test strength in the same muscles. An objective increase in strength (detected by manual muscle testing) immediately following the contraction bout is suggestive of LEMS and may be the only available test in resource-limited settings. This is less sensitive than formal RNS but highly specific when clearly positive.

• Imaging and malignancy screening: Chest CT imaging should be performed in all newly diagnosed LEMS patients to evaluate for underlying malignancy, particularly SCLC. Initial CT should have thin-section protocol with contrast enhancement to optimize detection of small lung lesions. Even with negative initial imaging, annual chest CT surveillance is recommended for at least 5 years given that malignancies can develop years after LEMS diagnosis. Additional imaging (abdominal CT, brain MRI, or other studies) may be guided by clinical suspicion and constitutional symptoms. PET-CT may have added sensitivity in some cases but is not routine.

• Diagnostic criteria for LEMS: The diagnosis requires clinical features (weakness, hyporeflexia) plus either (1) positive anti-VGCC antibodies, or (2) characteristic RNS findings (incremental response) or SFEMG abnormalities. The combination of clinical presentation, RNS/SFEMG findings, and VGCC antibody positivity establishes a definitive diagnosis with very high certainty.

• Differential diagnosis considerations:
• Myasthenia gravis: Ocular symptoms (ptosis, diplopia) are common in MG but rare in LEMS; MG typically shows decremental response on RNS without post-tetanic potentiation; post-tetanic potentiation is absent on RNS in MG but prominent in LEMS; respiratory and bulbar symptoms are more common in MG; anti-acetylcholine receptor and anti-MuSK antibodies are present in MG.
• Botulism: Autonomic symptoms (dry mouth, constipation) superficially resemble LEMS, but botulism is acute, presents with characteristic cranial nerve palsies (diplopia, ptosis, facial weakness) sparing extraocular muscles initially, and is linked to toxin exposure history; RNS shows the same incremental response as LEMS but malignancy screening is not indicated.
• **Guillain-Barré syndrome and chronic inflammatory demyelinating

Immediate stabilisation

• Assess respiratory and bulbar function first: although fulminant presentations are uncommon, serial forced vital capacity and negative inspiratory force should be trended in rapidly progressive weakness; declining values warrant ICU admission and non-invasive or invasive ventilation before hypercapnia appears.

First-line symptomatic therapy

• Potassium channel blockers (representative agent: amifampridine, 3,4-diaminopyridine): FDA-approved for LEMS in adults. Blockade of presynaptic voltage-gated K⁺ channels prolongs terminal depolarisation, holding residual P/Q-type calcium channels open longer, raising intraterminal Ca²⁺ and increasing acetylcholine quanta released per impulse — it corrects the exact defect described above. Titrate to effect; benefit is typically evident within days.
• Acetylcholinesterase inhibitors (representative agent: pyridostigmine): prolong the action of the small amount of acetylcholine that is released. Used as an adjunct, since the lesion is presynaptic release failure rather than receptor blockade, monotherapy responses are modest and less impressive than in myasthenia gravis.

Escalation / second-line

• Immunotherapy: corticosteroids (prednisone) with a steroid-sparing antimetabolite (azathioprine or mycophenolate) for patients with inadequate symptomatic control, especially non-paraneoplastic LEMS.
• IVIG or plasma exchange: for rapid but temporary benefit in severe or refractory disease; the American Academy of Neurology's evidence-based guideline on IVIG in neuromuscular disease supports its use in LEMS. Rituximab is reserved for refractory cases.

Definitive management

• Treat the tumour: in paraneoplastic disease, chemotherapy ± radiation for small-cell lung cancer per NCCN guidance is the single most effective intervention, and neurologic improvement often parallels tumour response. Immunosuppression should not delay oncologic therapy.

Contraindicated / use with caution

• Amifampridine in epilepsy (dose-dependent seizure risk) and caution with QT-prolonging drugs.
• Neuromuscular blocking agents: patients are exquisitely and unpredictably sensitive to both depolarising and non-depolarising agents — flag before any anaesthetic.
• Drugs that impair neuromuscular transmission: aminoglycosides, fluoroquinolones, magnesium, and calcium channel blockers can precipitate crisis.

Disease-related

• Respiratory failure (emergency): diaphragmatic and intercostal involvement from failed acetylcholine release; heralded by falling forced vital capacity, tachypnoea, orthopnoea, and paradoxical abdominal motion. A normal or rising PaCO₂ in a fatiguing patient is an ominous sign — intubate on trajectory, not on blood gas.
• Precipitated crisis after drug exposure or anaesthesia (emergency): aminoglycosides, fluoroquinolones, magnesium, calcium channel blockers, or neuromuscular blockers can convert compensated disease into ventilatory failure; prolonged post-operative paralysis is the classic presentation and sometimes the first clue to undiagnosed LEMS.
• Autonomic failure: severe constipation progressing to pseudo-obstruction/ileus, urinary retention, and orthostatic hypotension with syncope and fall-related fractures. Xerostomia causes dental caries.
• Undiagnosed small-cell lung cancer: the most consequential "complication" is missing the tumour; new weight loss, haemoptysis, or hyponatremia from SIADH should prompt repeat imaging.

Treatment-related

• Amifampridine: perioral and digital paresthesias are dose-limiting and near-universal; seizures are the feared dose-dependent toxicity from widespread K⁺ channel blockade.
• Pyridostigmine: muscarinic excess — cramping, diarrhoea, bronchorrhoea, bradycardia.
• Corticosteroids: hyperglycaemia, osteoporosis, infection; transient early worsening of weakness can occur when steroids are started.
• Azathioprine: myelosuppression and hepatotoxicity; check TPMT/NUDT15 status before starting, per standard US labeling, and monitor CBC.
• IVIG: thrombosis, aseptic meningitis, acute kidney injury, and anaphylaxis in IgA deficiency.
• Plasma exchange: citrate-induced hypocalcaemia (perioral tingling, Chvostek sign), hypotension, and central line complications.
• Rituximab: hepatitis B reactivation (screen first) and rare progressive multifocal leukoencephalopathy.

• The triad: proximal leg weakness + areflexia + autonomic features (dry mouth is the single most common). If all three appear in a middle-aged smoker, the answer is LEMS.
• Facilitation is the theme: strength, reflexes, and CMAP amplitude all improve after brief maximal exercise or high-frequency stimulation — the warm-up phenomenon and post-tetanic potentiation. On repetitive nerve stimulation, low baseline CMAP with a decrement at low frequency but a large incremental response after exercise is the money finding.
• Single best next step after diagnosis: CT chest to look for small-cell lung cancer — malignancy screening, not immunotherapy, comes first. Serologic confirmation is anti-P/Q-type voltage-gated calcium channel antibody.
• The association examiners test: SCLC. Treating the tumour treats the syndrome (NCCN-directed chemotherapy ± radiation), and LEMS may precede the cancer by months to years, so a negative first scan mandates continued surveillance.
• First-line drug: amifampridine (3,4-diaminopyridine) — blocks presynaptic K⁺ channels, prolongs depolarisation, increases Ca²⁺ entry and acetylcholine release. Its dose-limiting toxicity is seizures; avoid in epilepsy.
• Common distractor — myasthenia gravis: MG is postsynaptic, ocular/bulbar-predominant (ptosis, diplopia), reflexes are preserved, weakness worsens with use, and RNS shows decrement without facilitation. Choosing pyridostigmine monotherapy or thymectomy for LEMS is the classic wrong answer; there is no thymoma link.
• Second distractor — botulism: also presynaptic with an incremental response and autonomic dryness, but it is acute, produces descending paralysis with cranial nerve palsies and dilated, poorly reactive pupils, and requires antitoxin rather than cancer screening.
• Anaesthesia trap: profound, prolonged sensitivity to depolarising and non-depolarising neuromuscular blockers; unexplained failure to wean post-operatively can be the presenting event.